• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
MagazineHow I Got Started

How this 20-time founder with hundreds of patents got his start

By
Dinah Eng
Dinah Eng
Down Arrow Button Icon
By
Dinah Eng
Dinah Eng
Down Arrow Button Icon
October 1, 2019, 6:30 AM ET
VEN1019.Mir Imran-Rani Therapeutics-01
Mir Imran, founder of Rani Therapeutics, at its lab in San Jose. Photograph by Winni Wintermeyer for FortunePhotograph by Winni Wintermeyer for Fortune

Interview by Dinah Eng

Doing business came naturally to me. I was born in Hyderabad, India, and started building toys and selling them to my classmates when I was 8 or 9. I was infected by the entrepreneurial bug. By ninth grade, I was building radios in matchboxes that I sold at school. 

When I was growing up, there was a lot of corruption in India. At school, a kid from a wealthy family could bribe a teacher for a better grade. When I turned 15, I decided to leave India and sent applications to U.S. and Canadian universities. My parents didn’t know anything until I started getting acceptances. 

When the time came, I asked my dad for money. He tried to persuade me to study in India, but I said, “If you don’t give me the money, I’ll figure out a way to do it.” So he borrowed $4,000 from friends, even though borrowing money was frowned upon in India, and with that, I went to New York. In the days without Internet, it was quite an exciting journey. I was 17½ and enrolled at Rutgers. 

Back then, you could pay $200 per semester, and there was no limit on credit hours. So I fit all my courses for an electrical engineering degree into two years. I lived in a walk-in closet—subleasing it from another student for $20 a month—and had zero social life.

In 1975 I got excited about ­single-chip microcomputers. I started my first company, manufacturing home security systems, and was selling and installing them on the weekends. I financed everything with a credit card and made some money, but going to school full-time and running a business didn’t work, so I shut it down.

One year I saw a summer job posting for a school in northern New Jersey that served children with cerebral palsy. I spent time with a 7-year-old girl named Jenny who was quadriplegic, and I developed a device she could use with the muscles in her neck to communicate. That cemented my interest in bioengineering.

Then I got a scholarship to graduate school. I’ve never felt richer than when I started getting that $500-a-month stipend, and I saved the money to send back to my dad.

Toward the end of grad school, I started a second security company that failed because I didn’t understand how much money to raise, where to raise it, or what a business plan was. My entrepreneurial career started with two failures.

A professor insisted that I go to medical school. It was a great experience to understand the disease process and how poorly things were managed and treated. But as an engineer, I wanted to understand why things work the way they do and decided not to practice medicine. 

A cardiologist [Michel Mirowski] who wanted to create an implantable cardioverter-defibrillator invited me to work with him in Pittsburgh. He thought it would cost about $100,000 to produce the device, but it ended up costing $27 million and took six years to develop. Raising the money and talking to the FDA taught me a lot. I developed the second-generation device, which got FDA approval. Eli Lilly came in as an investor and eventually bought the company. So in 1985, I left for California.

Realtors at the time were using a brass lockbox with a universal key that thieves stole to obtain house keys. While I was selling my home, it got burglarized this way, so I thought, I have to fix that. In the late ’80s, I started a company to invent an electronic lockbox that keeps track of every realtor who enters, with a time and date, which has become the industry standard. I sold that company to Supra.

Early on, my biggest challenge was understanding business and fundraising. I had such a hard time asking people for investment. I had the mortal fear that the company could fail, and I could never show my face again. 

I was talented at science and technology, but investors saw me as a techie and not as a business guy. A lot of scientists stop working in the lab when they get into business, but I kept developing products while I grew my businesses.

My plan was to found a life-science com­pany for each medical device I invented. Invariably, a larger company would be looking for new categories of therapy, wanting to own those, so they’d come and make an offer. I even took three companies public—they still got acquired.

I was starting companies at a pace of one a year because there were so many problems I wanted to solve. I’d hire a CEO, do some work, build a team, and start another company.

In 1998, some friends and I started Adam Ventures. We wrote small checks to 81 dotcoms and 37 med-tech companies. Many of the med-tech companies did well, but of the 81 tech companies, 78 went kaput. Only three made money, and one of them was Google.

The problem we’re addressing today at Rani Therapeutics is how to deliver protein drugs orally. We plan to convert insulin and another diabetes drug into an oral pill. This will improve patient compliance and get better outcomes, taking away the need for self-injections. 

You can treat multiple sclerosis, Crohn’s disease, and a long list of chronic diseases with protein drugs, so we could have a transformative effect on the treatment of 30 to 40 diseases with this process. We’ve raised $140 million so far from investors like Google and Novartis, and are currently in clinical trials in Australia.

I realized early on that each company can take six to eight years to reach clinical success. That would have meant I could solve only five problems and take them to completion within my lifetime, if taken one at a time. So I decided to work on multiple problems. At any given time, I have six to eight companies at various stages of development. I doubt I’ll ever retire because I’ll always have six to eight unfinished businesses. My hope is that someone will take them over and complete them after I die.

I’m constantly pushing the boundaries of my knowledge. The young man is gone, and in his place is an old, bald guy, but I’m working harder than ever. I have the same curiosity and passion, and unless the body gives out, I hope to keep producing for years to come. 

My Best Advice 

Mir Imran, founder of Rani Therapeutics

Choose the right problem. 

To me, innovation is about identifying a problem that’s worthy of a solution and framing it without thinking about the methods you were taught. The solution needs to have dramatic impact rather than incremental improvement. To choose the right problem, look at current solutions, market potential, IP landscape, potential for reimbursement, and other factors.

Imran by the Numbers

—Founded 22 life-science companies.
—Was issued 364 patents, with an additional 343 patents pending.
—Invested in over 100 health care companies.

A version of this article appears in the October 2019 issue of Fortune with the headline “Master of Invention.”

More must-read stories from Fortune:

—Billionaire Ken Griffin to fund $10 million Parkinson’s competition with Michael J. Fox Foundation
—How people are using smartwatches to lose weight and stay healthy
—Why the cost of U.S. health insurance is surging
—”Virtual care is the great equalizer in healthcare,” says Teladoc Health CEO
—Listen to our audio briefing, Fortune 500 Daily
Follow Fortune on Flipboard to stay up-to-date on the latest news and analysis.

Sign up for the Fortune Features email list so you don’t miss our biggest features, exclusive interviews, and investigations.

About the Author
By Dinah Eng
See full bioRight Arrow Button Icon

Latest from the Magazine

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest from the Magazine

MagazineIPOs
IPO boom times are back, with SpaceX and OpenAI on investors’ 2026 wish list. But be careful what you buy
By Jeff John RobertsJanuary 15, 2026
22 hours ago
MagazineNetflix
Netflix’s $82.7 billion rags-to-riches story: How the DVD-by-mail company swallowed Hollywood
By Natalie JarveyJanuary 10, 2026
6 days ago
MagazineCustomer Experience
Survey overload: Companies are inundating customers with endless surveys—and getting worse insights
By Phil WahbaDecember 28, 2025
19 days ago
MagazineData centers
At the edges of the AI data center boom, rural America is up against Silicon Valley billions
By Sharon GoldmanDecember 27, 2025
20 days ago
MagazineWarren Buffett
Warren Buffett: Business titan and cover star
By Indrani SenDecember 7, 2025
1 month ago
MagazineMarkets
Why an AI bubble could mean chaos for stock markets—and how smart investors are protecting their portfolios
By Alyson ShontellDecember 3, 2025
1 month ago

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Most Popular

placeholder alt text
Personal Finance
Peter Thiel makes his biggest donation in years to help defeat California’s billionaire wealth tax
By Nick LichtenbergJanuary 14, 2026
2 days ago
placeholder alt text
Europe
Americans have been quietly plundering Greenland for over 100 years, since a Navy officer chipped fragments off the Cape York iron meteorite
By Paul Bierman and The ConversationJanuary 14, 2026
1 day ago
placeholder alt text
Health
The head of marketing at Slate posted on LinkedIn requesting cleaning services as a benefit at her company. The next day, HR answered her call
By Sydney LakeJanuary 15, 2026
1 day ago
placeholder alt text
Success
Despite a $45 million net worth, Big Bang Theory star still works tough, 16-hour days—he repeats one mantra when overwhelmed
By Orianna Rosa RoyleJanuary 15, 2026
24 hours ago
placeholder alt text
Economy
California's wealth tax doesn't fix the real problem: Cash-poor billionaires who borrow money, tax-free, to live on
By Nick LichtenbergJanuary 14, 2026
2 days ago
placeholder alt text
Politics
One year after Bill Gates surprised with the choice to close his foundation by 2045, he's cutting staff jobs
By Stephanie Beasley and The Associated PressJanuary 14, 2026
2 days ago